Results 11 to 20 of about 752,942 (288)
The capture proteasome assay (CAPA) to evaluate subtype-specific proteasome inhibitors [PDF]
Data in Brief, 2015 We recently developed a new assay to measure proteasome activity in vitro (CAPA for capture proteasome assay) [1], based on proteasome capture on an antibody-coated plate.
Nathalie Vigneron +2 more
doaj +2 more sources
Proteasome Inhibitors in Waldenström Macroglobulinemia
Hematology/Oncology Clinics of North America, 2018 Waldenström macroglobulinemia (WM) remains an incurable B-cell lymphoproliferative disorder, yet therapy is only considered for patients with symptomatic disease. Primary therapy options for WM include combinations based on anti-CD20 monoclonal antibodies, mainly rituximab. However, proteasome inhibitors have become an important part of WM therapy both
Kastritis, Efstathios +1 more
core +7 more sources
Joining the Army of Proteasome Inhibitors [PDF]
Chemistry & Biology, 2008 An article in this issue of Chemistry & Biology (Hines et al., 2008) and a recent study in Nature (Groll et al., 2008) establish three natural products as novel proteasome inhibitors. These inhibitors, discovered in an unusual way, reveal a different mechanism of proteasome inhibition and suggest new therapeutic application of its inhibitors.
Kisselev, Alexei F.
openaire +3 more sources
The ubiquitin‐proteasome pathway and proteasome inhibitors [PDF]
Medicinal Research Reviews, 2001 AbstractThe ubiquitin‐proteasome pathway has emerged as a central player in the regulation of several diverse cellular processes. Here, we describe the important components of this complex biochemical machinery as well as several important cellular substrates targeted by this pathway and examples of human diseases resulting from defects in various ...
J, Myung, K B, Kim, C M, Crews
openaire +2 more sources
Microbial proteasomes as drug targets.
PLoS Pathogens, 2021 Proteasomes are compartmentalized, ATP-dependent, N-terminal nucleophile hydrolases that play essentials roles in intracellular protein turnover. They are present in all 3 kingdoms.
Hao Zhang, Gang Lin
doaj +3 more sources
Postnatal proteasome inhibition induces neurodegeneration and cognitive deficiencies in adult mice: a new model of neurodevelopment syndrome. [PDF]
PLoS ONE, 2011 Defects in the ubiquitin-proteasome system have been related to aging and the development of neurodegenerative disease, although the effects of deficient proteasome activity during early postnatal development are poorly understood.
Rocío Romero-Granados +3 more
doaj +1 more source
Cardiovascular toxicity of proteasome inhibitors in multiple myeloma therapy
, 2022 The treatment for multiple myeloma has advanced significantly over the past few decades. Proteasome inhibitors have become the cornerstone of the treatment of multiple myeloma.
Huang, Shan +6 more
core +1 more source
Molecules, 2022 Proteasome inhibitors have shown relevant clinical activity in several hematological malignancies, namely in multiple myeloma and mantle cell lymphoma, improving patient outcomes such as survival and quality of life, when compared with other therapies ...
Carlota Leonardo-Sousa +7 more
doaj +1 more source
Blood Cancer Journal, 2020 Protein homeostasis is critical for maintaining eukaryotic cell function as well as responses to intrinsic and extrinsic stress. The proteasome is a major portion of the proteolytic machinery in mammalian cells and plays an important role in protein ...
Yanyan Gu +9 more
doaj +1 more source
Proteasome inhibitors alter levels of intracellular peptides in HEK293T and SH-SY5Y cells. [PDF]
PLoS ONE, 2014 The proteasome cleaves intracellular proteins into peptides. Earlier studies found that treatment of human embryonic kidney 293T (HEK293T) cells with epoxomicin (an irreversible proteasome inhibitor) generally caused a decrease in levels of intracellular
Sayani Dasgupta +6 more
doaj +1 more source